Back to Authors

Colunga-Lozano, Luis E

0000-0001-7737-4914

Mayo Clinic

Health Science Center, Universidad de Guadalajara, Guadalajara, Mexico.

Citations 3

American Society of Hematology 2023 guidelines for management of venous thromboembolism: thrombophilia testing
Middeldorp, Saskia , Nieuwlaat, Robby , Kreuziger, Lisa Baumann , Coppens, Michiel , Houghton, Damon E. , James, Allison , Lang, Eddy , Moll, Stephan , Myers, Tarra, Bhatt, Meha , Zhang, Yuan , Schünemann, Holger J. , Iorio, Alfonso , Baumann Kreuziger, Lisa , Houghton, Damon E , James, Andra H , Colunga-Lozano, Luis E , Karam, Samer G , Zhang, Yuan , Wiercioch, Wojtek , Schünemann, Holger J , Iorio, Alfonso , Chai‐Adisaksopha, Chatree , Colunga‐Lozano, Luis Enrique , Wiercioch, Wojtek

Blood Advances | May 17, 2023 | Volume: 7 | Issue: 22 | Pages: 7101-7138

10.1182/bloodadvances.2023010177 Get It

Background Hereditary and acquired thrombophilia are risk factors for venous thromboembolism (VTE). Whether testing helps guide management decisions is controversial. Objective These evidence-based guidelines from the American Society of Hematology (ASH) intend to support decision making about thrombophilia testing. Methods ASH formed a multidisciplinary guideline panel covering clinical and methodological expertise and minimizing bias from conflicts of interest. The McMaster University GRADE Centre provided logistical support, performed systematic reviews, and created evidence profiles and evidence-to-decision tables. The Grading of Recommendations Assessment, Development, and Evaluation approach (GRADE) was used. Recommendations were subject to public comment. Results The panel agreed on 23 recommendations regarding thrombophilia testing and associated management. Nearly all recommendations are based on very low certainty in the evidence due to modeling assumptions. Conclusions The panel issued a strong recommendation against testing the general population before starting combined oral contraceptives (COCs) and conditional recommendations for thrombophilia testing in the following scenarios: (a) patients with VTE associated with nonsurgical major transient or hormonal risk factors; (b) patients with cerebral or splanchnic venous thrombosis, in settings where anticoagulation would otherwise be discontinued; (c) individuals with a family history of antithrombin, protein C, or protein S deficiency when considering thromboprophylaxis for minor provoking risk factors and for guidance to avoid COCs/hormone replacement therapy; (d) pregnant women with a family history of high-risk thrombophilia types; and (e) patients with cancer at low or intermediate risk of thrombosis and with a family history of VTE. For all other questions, the panel provided conditional recommendations against testing for thrombophilia.
American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults
Abel, Gregory A. , Altman, Jessica K. , Buckstein, Rena , Choe, Hannah , Erba, Harry P. , Hourigan, Christopher S. , LeBlanc, Thomas W. , Litzow, Mark R. , MacEachern, Janet , Michaelis, Laura C. , O’Dwyer, Kristen M. , Rosko, Ashley , Stone, Richard M. , Agarwal, Arnav , Colunga‐Lozano, Luis Enrique , Brignardello‐Petersen, Romina , Agarwal, Arnav , Erba, Harry Paul , Hourigan, Christopher S , Leblanc, Thomas , Colunga-Lozano, Luis E , Sekeres, Mikkael A. , Guyatt, Gordon , Alibhai, Shabbir M.H. , Desai, Pinkal , Mukherjee, Sudipto , O'Dwyer, Kristin , Chang, Yaping , Hao, Qiukui

Blood Advances | August 6, 2020 | Volume: 4 | Issue: 15 | Pages: 3528-3549

10.1182/bloodadvances.2020001920 Get It

Abstract Background: Older adults with acute myeloid leukemia (AML) represent a vulnerable population in whom disease-based and clinical risk factors, patient goals, prognosis, and practitioner- and patient-perceived treatment risks and benefits influence treatment recommendations. Objective: These evidence-based guidelines of the American Society of Hematology (ASH) are intended to support patients, clinicians, and other health care professionals in their decisions about management of AML in older adults. Methods: ASH formed a multidisciplinary guideline panel that included specialists in myeloid leukemia, geriatric oncology, patient-reported outcomes and decision-making, frailty, epidemiology, and methodology, as well as patients. The McMaster Grading of Recommendations Assessment, Development and Evaluation (GRADE) Centre supported the guideline-development process, including performing systematic evidence reviews (up to 24 May 2019). The panel prioritized clinical questions and outcomes according to their importance to patients, as judged by the panel. The panel used the GRADE approach, including GRADE’s Evidence-to-Decision frameworks, to assess evidence and make recommendations, which were subject to public comment. Results: The panel agreed on 6 critical questions in managing older adults with AML, mirroring real-time practitioner-patient conversations: the decision to pursue antileukemic treatment vs best supportive management, the intensity of therapy, the role and duration of postremission therapy, combination vs monotherapy for induction and beyond, duration of less-intensive therapy, and the role of transfusion support for patients no longer receiving antileukemic therapy. Conclusions: Treatment is recommended over best supportive management. More-intensive therapy is recommended over less-intensive therapy when deemed tolerable. However, these recommendations are guided by the principle that throughout a patient’s disease course, optimal care involves ongoing discussions between clinicians and patients, continuously addressing goals of care and the relative risk-benefit balance of treatment.
Modafinil for people with schizophrenia or related disorders
Ortiz‐Orendain, Javier , Covarrubias-Castillo, Sergio Armando, Vázquez‐Álvarez, Alan Omar , Castiello, Santiago , Quiñones, Gustavo E Arias, Seegers, Maya, Colunga‐Lozano, Luis Enrique , Colunga-Lozano, Luis E , Quiñones, Gustavo E. Arias

Cochrane Database of Systematic Reviews | December 11, 2019 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/14651858.cd008661.pub2 Get It